洛铂联合长春瑞滨治疗晚期乳腺癌33例的临床疗效

Lobaplatin plus vinorelbine in the treatment of advanced breast cancer

目的：观察长春瑞滨（NVB）联合洛铂（LBP）组成NL方案治疗晚期乳腺癌的疗效和不良反应。方法：从2004年1月～2005年10月，采用NVB加LBP的联合化疗方案治疗晚期乳腺癌33例，LBP30mg／m^2，第1天，静脉滴注3小时；NVB25mg／m^2，第1、8天，静脉滴注30分钟，21天为1周期。结果：全组33例共完成105个周期，中位3周期（2-4周期），均可评价疗效。获CR1例，PR13例，SD11例，PD8例，RR为42．4％，肿瘤控制率DCR（CR＋PR＋SD）为75．8％．中位缓解期为4个月（1～17个月）。主要不良反应为骨髓抑制，其中Ⅲ-Ⅳ度粒细胞减少发生率为57．6％，Ⅲ度血小板减少发生率为9.1％；非血液学毒性轻微，可以耐受。结论：洛铂联合长春瑞滨组成NL方案治疗局部晚期及转移性乳腺癌疗效较好．不良反应可以耐受，在加强支持治疗（应用造血因子）的基础上，可以考虑作为二线治疗或解救化疗方案。

Objective： To evaluate the results of combination chemotherapy with Vinorelbine plus Lobaplatin （DDP） in the treatment of advanced breast cancer. Methods： From January 2004 to October 2005, 33 patients with advanced breast cancer were enrolled in this study. Vinorelbine was given at a dose 25mg/m^2 on day 1 and 8, with Lobaplatin 30mg/m^2 dayl of a 21 day cycle. Results： A total of 105 cycles of chemotherapy were given,with a median of 3 cycles per patient （ range, 2 to 4 cycles）. The overall response rate was 42. 4% with CR 3.0%. The median time of response duration was 4 months （ range, 1 to 17 months）. The main doselimiting toxicity was myelosuppression with grade Ⅲ and Ⅳ neutropenia being in 57.6% and grade Ⅲ thrombocytopenia in 9. 1%. Non-hemotologic toxicities were modest and recoverable on discontinuation of therapy. Conclusion： This combination therapy regimen shows promising results with acceptable toxicity, and on the basis of good support treatment （the application of G-CSF）, it could be considered as a therapeutic salvage treatment regimen for advanced breast cancer.